Kutatási jelek – Signal Engine

• Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy — Renal cell carcinoma
• Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era — Renal cell carcinoma
• SERPINH1 derived from cancer-associated fibroblasts promotes epithelial‑mesenchymal transition in clear cell renal cell carcinoma — Hepatocellular carcinoma
• Lipid metabolic reprogramming in NSCLC: mechanisms, microenvironment crosstalk, and therapeutic opportunities — NSCLC
• Trends in treatment and survival of stage IV non‑squamous NSCLC from 2010 to 2022 — NSCLC
• Variant allele frequency as a predictor of treatment response to osimertinib in EGFR‑mutated NSCLC — NSCLC
• Frontiers | Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy — NSCLC
• Frontiers | Precision immuno-oncology in NSCLC: integrating ADCs, therapeutic vaccines, and adoptive cell therapies for next-generation systemic treatment — NSCLC
• A novel bispecific antibody targeting Frizzled7/PD‑L1 overcomes NSCLC resistance to atezolizumab by reprogramming tumor microenvironment — NSCLC
• AI in esophageal cancer: advances, barriers to clinical translation, and perspectives for digital health — Esophageal cancer
• Antibody‑Drug Conjugates in the Treatment of Esophageal Cancer — Esophageal cancer
• Early esophageal cancer diagnosis in Central Oromia, Ethiopia: patient and provider perspectives on barriers and facilitators — Esophageal cancer
• Advances in epigenetic therapy for esophageal cancer — Esophageal cancer
• Frontiers | Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies — Hepatocellular carcinoma
• Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective — Esophageal cancer
• Immune exhaustion in esophageal cancer: interferon pathway dysregulation and neoadjuvant therapy response — Esophageal cancer
• Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox — Esophageal cancer
• Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a multicenter retrospective study — Acute lymphoblastic leukemia
• Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study — Acute lymphoblastic leukemia
• Total body irradiation versus chemotherapy before stem cell transplantation in children aged two to four with acute lymphoblastic leukemia—an EBMT pediatric diseases working party study — Acute lymphoblastic leukemia